BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Massachusetts Institute of Technology

Headquarters: Cambridge, MA, United States of America
Year Founded: 1861
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Nov 27, 2024
Emerging Company Profile

Valora: Blocking cancer’s immune evasion via glycan targeting

San Diego-based company’s antibody-lectin chimeras act as molecular decoys to disrupt cellular interactions
BioCentury | Aug 3, 2024
Deals

Biotechs find problem-solving in academia, and mostly outside the big hubs 

Academia-biotech deals span innovative assets to tissue bank resources to enabling technologies
BioCentury | Jul 25, 2024
Finance

Venture Report: Third Arc’s $165M series A; Brenig heads for clinic with $65M round

Plus: Flagship-backed Abiologics launches; and rounds for GRO, Autobahn and Rona
BioCentury | Apr 30, 2024
Distillery Therapeutics

Host SCGB1D2 for Lyme disease

BioCentury | Mar 16, 2024
Discovery & Translation

Science spotlight: Boosting immunotherapy by counteracting Tregs in tumor-draining lymph nodes and more

BioCentury’s roundup of translational innovations
BioCentury | Feb 24, 2024
Discovery & Translation

Science spotlight: New class of molecular glues, gene therapy for FTD/ALS and more

BioCentury’s roundup of translational innovations
BioCentury | Feb 21, 2024
Distillery Therapeutics

Increasing Kupffer cell GPR3 activation for obesity

BioCentury | Feb 9, 2024
Product Development

Getting the most out of digital endpoints: case studies from Verge’s CMO

Perspectives from Diego Cadavid on Verge’s digital-first Phase Ib strategy for ALS, and on building a pivotal endpoint using an Xbox sensor
BioCentury | Jan 6, 2024
Product Development

Flagship’s AI hub: making models that co-pioneer

The VC’s Pioneering Intelligence unit is experimenting with new methods, operationalizing tools, and creating companies
BioCentury | Dec 13, 2023
Finance

Dec. 12 Quick Takes: Targeted genomic DNA insertion company Tome launches with $213M

Plus: Bicara’s latest big round is a $165M series C, Shinobi launches, Pfizer readies to close Seagen deal and more
Items per page:
1 - 10 of 795